Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07660666 · ClinicalTrials.gov registry record · NA
Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor
A NA study, sponsored by OHSU Knight Cancer Institute.
- Not yet
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT07660666 is a NA study that has not yet begun recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 50 participants.
The verdict
NCT07660666, a NA study, has not yet begun recruiting, sponsored by OHSU Knight Cancer Institute.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This clinical trial tests the feasibility of patient reported outcomes monitoring with early, rapid immunotherapy toxicity subspecialty care to improve side effect management for patients with melanoma receiving an immune checkpoint inhibitor. Immune checkpoint inhibitors have improved outcomes for patients with advanced melanoma, but their use is frequently complicated by immune related adverse events (irAEs). IrAEs can affect any organ system, range in severity from mild to life threatening, and often require a pause or stopping of immunotherapy treatment. Early identification and management of irAEs may reduce progression to severe toxicity. Electronic patient self reporting of symptoms with ways to support early involvement of non oncology subspecialists may be a feasible way to improve side effect management for patients with melanoma receiving an immune checkpoint inhibitor.
Interventions
- OTHER Survey Administration
- OTHER Electronic Health Record Review
- OTHER Internet-Based Intervention
- BEHAVIORAL Patient Navigation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-11-01 |
| Est. Completion | 2029-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07660666
The ClinicalTrials.gov registry entry for NCT07660666 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Survey Administration is the first listed.
NCT07660666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07660666 about?
NCT07660666 is a clinical study titled "Feasibility of an Enhanced Symptom Monitoring and Expedited Subspecialty Care Referral Intervention to Improve Side Effect Management for Patients With Melanoma Receiving an Immune Checkpoint Inhibitor". This clinical trial tests the feasibility of patient reported outcomes monitoring with early, rapid immunotherapy toxicity subspecialty care to improve side effect management for patients with melanoma receiving an immune checkpoint inhibitor. Immune checkpoint inhibitors have improved outcomes for ...
What is the current status of trial NCT07660666?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-11-01. Estimated completion is 2029-06-01.
What interventions are being tested in trial NCT07660666?
The interventions under investigation include: Survey Administration (OTHER), Electronic Health Record Review (OTHER), Internet-Based Intervention (OTHER), Patient Navigation (BEHAVIORAL).
Who is sponsoring clinical trial NCT07660666?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.